Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Cost of Revenue: 2023-2025

Historic Cost of Revenue for Krystal Biotech (KRYS) over the last 2 years, with Sep 2025 value amounting to $4.3 million.

  • Krystal Biotech's Cost of Revenue fell 36.22% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year increase of 19.03%. This contributed to the annual value of $20.1 million for FY2024, which is 548.38% up from last year.
  • Latest data reveals that Krystal Biotech reported Cost of Revenue of $4.3 million as of Q3 2025, which was down 40.50% from $7.2 million recorded in Q2 2025.
  • Over the past 5 years, Krystal Biotech's Cost of Revenue peaked at $7.2 million during Q2 2025, and registered a low of $223,000 during Q3 2023.
  • In the last 3 years, Krystal Biotech's Cost of Revenue had a median value of $4.9 million in 2024 and averaged $4.4 million.
  • In the last 5 years, Krystal Biotech's Cost of Revenue spiked by 2,897.31% in 2024 and then crashed by 36.22% in 2025.
  • Quarterly analysis of 3 years shows Krystal Biotech's Cost of Revenue stood at $2.9 million in 2023, then surged by 72.38% to $4.9 million in 2024, then slumped by 36.22% to $4.3 million in 2025.
  • Its last three reported values are $4.3 million in Q3 2025, $7.2 million for Q2 2025, and $5.0 million during Q1 2025.